[{"Assets_0_Q2_USD":1276100000.0,"CommonStockSharesOutstanding_0_Q2_shares":68100000.0,"EarningsPerShareBasic_1_Q2_USD":0.09,"EarningsPerShareBasic_2_Q2_USD":0.07,"EarningsPerShareDiluted_1_Q2_USD":0.09,"EarningsPerShareDiluted_2_Q2_USD":0.07,"NetIncomeLoss_1_Q2_USD":5900000.0,"NetIncomeLoss_2_Q2_USD":4700000.0,"StockholdersEquity_0_Q2_USD":732900000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":68300000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":68900000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":68200000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":68500000.0,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20161231","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20170208"}]